For the quarter ending 2026-03-31, LABT had -$224,691 decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 |
|---|---|
| Net loss | -923,291 |
| Depreciation | 1,159 |
| Stock-based compensation | 46,180 |
| Amortization of right-of-use asset | 29,333 |
| Prepaid expenses and other current assets | -30,072 |
| Accounts payable | 166,788 |
| Accrued expenses and other current liabilities | 290,851 |
| Accrued interest related parties | 38,219 |
| Operating lease liability | -29,002 |
| Net cash used in operating activities | -349,691 |
| Proceeds from loans from related parties | 125,000 |
| Net cash provided by financing activities | 125,000 |
| Net decrease in cash and cash equivalents | -224,691 |
| Cash and cash equivalents beginning of period | 236,400 |
| Cash and cash equivalents end of period | 11,709 |
Lakewood-Amedex Biotherapeutics Inc. (LABT)
Lakewood-Amedex Biotherapeutics Inc. (LABT)